SYMBIOTEC

September 21, 2026

To,
The Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip code: 544889

To,
The Listing Department
National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Symbol: SYMBIOTEC

Subject: Investor Release of Financial Results for the 1st Quarter ended June 30, 2026

Dear Sir/Ma'am,

We are enclosing herewith the Investor Release being issued by the Company, Symbiotec Pharmalab Limited for the 1st Quarter ended June 30, 2026.

The aforesaid information shall also be made available on the website of the Company at https://www.symbiotec.com/

This is for your Information and Records.

Thanking you,

For Symbiotec Pharmalab Limited

SALIL JAIN
Digitally signed by SALIL JAIN
Date: 2026.09.21 19:41:49 +05'30'

Salil Jain
Company Secretary & Compliance Officer

Registered Office & Works:
Symbiotec Pharmalab Limited
(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)
385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India
Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,
Email ID : symbiotec@symbiotec.com, **Website** : www.symbiotec.com
CIN: U24232MP2002PLC015293

PRESS RELEASE

Symbiotec Pharmalab delivers steady performance for Q1FY27

Indore | September 21, 2026

Symbiotec Pharmalab Limited ("Symbiotec"), science-driven pharmaceutical and biotechnology company and a global leader in corticosteroid and steroidal-hormone APIs, today announced its financial results for the quarter ended June 30, 2026.

Financial Performance Snapshot Q1FY27

Particulars (Rs. in Crs)	Q1FY27	Q1FY26	Remarks
API Business			
Operating Revenue	215.3	203.2	• API **Gross margins upwards of 60%** • API **EBIDTA margins steady at ~30%** driven by revenue growth and favourable sales mix
EBIDTA	65.8	60.1	
Consolidated Performance			
Consol. Revenues	218.2	203.2	• Drag of expenses from new businesses not yet generating revenues - Opex - Rs. 23 crs - Depreciation - Rs. 12 crs • Revenue generation from various new businesses expected to commence **in next 6-12 months**
Consol. EBIDTA	45.2	58.0	
Consol. PAT	14.1	29.9	

Key Operational Highlights

APIs Products

- **Sales growth steady at 6% Y-o-Y for Q1 FY27**
    - Growth further expected to pick up in subsequent quarters
- **Successfully completed 4 major regulatory audits recently:**
    - EUGMP audits in Rau and Pithampur plants in March 2026
        - Approval certification received for both plants
    - USFDA audit in Mar-Apr 2026 at Rau plant – EIR received
    - USFDA audit in Aug 2026 at Pithampur plant – EIR awaited

Complex Injectables

- **Licensing agreement for distribution of two DCV products in US**
    - Term-sheet signed, Agreement at advanced stage, expected to sign off shortly
- **Successfully filed first molecule ANDA for DCV in September 2026**
    - First generic filing for the DCV product in US market
- **Filing of second ANDA scheduled for early Q4 FY27**

Biotech - CDMO Services

- **Industrial Biotech**
    - Customers on-boarded
    - 10 years take-or-pay agreement with US based Alternate Protein player in place
    - 10 years take-or-pay term-sheet with Europe based Alternate Protein player in place, agreement in advanced stage

- **Bio-Pharmaceutical : Insulin Drug Substance (DS)**
  - 5 years take or pay agreement in place, Capex on track; filing regulatory approval in Q4FY27

Capex Update

- **Total gross capex of approx. Rs. 1,666 crs est by end FY27**
  - 61% of such total gross capex or Rs. 1,000 Crs invested in new revenue generating businesses
  - Revenue for majority of new capacities already contracted
  - Such revenues to commence in the next 6–12 months

- Q1FY27 gross capex invested ~Rs. 68 crs

Net Debt

- Net Debt as on 30th June 2026 **~Rs. 398 crs**
- Post IPO proceeds, Net Debt as on 20th September **~ Rs. 326 crs**

🔷 **Management Commentary**

Mr. Anil Satwani, Chairman & Managing Director, Symbiotec Pharmalab Limited, said:

"Our first results as a listed company reflect a business with a steady growing core and two new growth engines for the future.

The API business — built over three decades of steroid chemistry depth and regulated-market presence — delivered steady revenue growth of 6% and EBITDA growth of 9%. Consistent, cash-generative growth here is what allows us to build the new growth engines with conviction.

In Complex Injectables, we filed our first ANDA from our Dual Chamber Vial platform this quarter — one more step closer to commercialization and are progressing well towards a second filing in the coming months. Behind these filings sits a pipeline that is getting deeper: our development work is steadily adding new molecules to the DCV portfolio and opening adjacent formats, extending the platform into new therapeutic segments.

In Biotech - CDMO Services, engagement is widening steadily. New customers are exploring manufacturing programmes across our capabilities, and existing conversations are progressing favourably. This is a business built on trust and technical credibility — these innovator customers take time to build the relationship, but are very sticky delivering a highly predictable, recurring revenue stream through take-or-pay arrangements.

We have built a differentiated business at Symbiotec"

About Symbiotec Pharmalab Limited ('Symbiotec')

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. Founded in 1995, the Company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs). Symbiotec serves over 200 customers across more than 40 countries through three complementary business verticals — APIs, CDMO services and Complex Injectables — supported by four manufacturing facilities in Madhya Pradesh, India, with approvals from USFDA, EU-GMP, WHO-GMP, Japan-PMDA and other leading global regulators.

Disclaimer

Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management 's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of Symbiotec Pharmalab Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

For further information please contact

Company	Investor Relations Advisors
Symbiotec Pharmalab Limited CIN No: U24232MP2002PLC015293 Email ID: investorrelations@symbiotec.com	**Strategic Growth Advisors Pvt Ltd.** CIN No: U74140MH2010PTC204285 Sagar Shroff / Prabjeet Singh Tank Email id: sagar.shroff@sgapl.net / prabjeet.singh@sgapl.net Tel No: +91 98205 19303 / +91 81690 49325